江苏康缘药业股份有限公司监事会 关于回购注销公司 2022 年度限制性股票激励计划剩余全部 限制性股票相关事项的核查意见 回购注销前述 155 名激励对象已授予但尚未解除限售的限制性股票符合 《管理办法》《激励计划》的有关规定。本次回购注销事项已履行相应的审议 程序，回购注销的原因、数量及价格合理、合法、有效，上述事项不会导致公 司股票分布情况不符合上市条件的要求，也不存在损害公司及股东利益的情形。 综上，同意公司回购注销前述 155 名激励对象 330.03 万股已授予但尚未解除限 售的限制性股票。 江苏康缘药业股份有限公司监事会 2025 年 4 月 2 日 江苏康缘药业股份有限公司（以下简称"公司"）监事会根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司股权激励管理办法》 （以下简称"《管理办法》"）等相关法律、法规和规范性文件以及《公司章 程》的有关规定，对回购注销公司 2022 年度限制性股票激励计划（以下简称 "本次激励计划"）剩余全部限制性股票相关事项进行了核查，发表核查意见 如下： 根据《2022 年度限制性股票激励计划（更正后）》（以下简称"《激励计 划》"）的规定，因 20 ...

证券简称：康缘药业 证券代码：600557 公告编号：2025-007 江苏康缘药业股份有限公司 第八届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（简称"公司"）第八届董事会第十六次会议通知 于 2025 年 3 月 22 日以书面文件、电话和电子邮件方式发出，会议于 2025 年 4 月 2 日在公司会议室以现场结合通讯方式召开。应出席会议董事 9 人，实际出席会议 董事 9 人。本次会议的召开符合《公司法》等法律法规以及《公司章程》的规定。 会议由董事长肖伟先生主持，会议以举手和通讯表决的方式审议通过以下议案，并 形成决议。 一、审议通过了《2024 年年度报告及其摘要》 本议案已经公司第八届董事会审计委员会 2025 年第一次会议审议通过，并同 意提交公司董事会审议。 具体内容详见公司同日于上海证券交易所网站 www.sse.com.cn 披露的公司 《2024 年年度报告》和《2024 年年度报告摘要》。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 二 ...

Financial Performance - The company's consolidated revenue for 2024 was CNY 3.90 billion, a decrease of 19.86% compared to CNY 4.87 billion in 2023[25]. - Net profit attributable to shareholders was CNY 391.86 million, down 15.58% from CNY 464.16 million in the previous year[25]. - Basic earnings per share decreased to CNY 0.68, a decline of 16.05% from CNY 0.81 in 2023[26]. - The company reported a total revenue of CNY 389,766.85 million, a decrease of 19.86% year-on-year[73]. - The net profit attributable to shareholders was CNY 39,186.21 million, down 15.58% compared to the previous year[73]. - Operating cash flow decreased by 27.75% to CNY 70,248.82 million[73]. - The company's total revenue for the industrial sales segment was approximately ¥3.86 billion, with a gross margin of 73.61%, reflecting a year-over-year revenue decline of 20.14% and a cost reduction of 17.45%[78]. - The revenue from injection solutions decreased by 38.33% year-over-year, while the cost decreased by 40.95%, primarily due to lower sales of specific products[79]. - The revenue from gel formulations increased by 82.48% year-over-year, with costs rising by 120.05%, driven by higher sales of a particular gel product[79]. Dividend Policy - The company plans not to distribute cash dividends or issue bonus shares for the fiscal year 2024, considering current operational needs and long-term development[8]. - The total cash dividend amount for the recent fiscal year was RMB 185,909,622.90, representing 47.44% of the net profit attributable to shareholders[195]. - Over the last three fiscal years, the cumulative cash dividend amount (including tax) was RMB 344,655,007.44, with a cash dividend ratio of 128.99% based on the average annual net profit of RMB 411,321,445.20[197]. - The company did not propose a cash profit distribution plan despite having positive distributable profits for the reporting period[193]. - The company has implemented a cash dividend policy that aligns with regulatory guidelines and has not made adjustments during the reporting period[191]. Research and Development - The company is committed to a research and development model that integrates traditional Chinese medicine with chemical and biological drugs[16]. - The company has applied for 52 invention patents, with 29 newly authorized, and published 47 Chinese papers and 33 SCI papers[38]. - The company has a research team of nearly 800 professionals across various fields, enhancing its R&D capabilities[69]. - The company reported a total R&D expenditure of approximately ¥654.4 million, accounting for 16.79% of total revenue, with capitalized R&D representing 2.49%[90]. - The company is focusing on expanding its product line with new drugs targeting various conditions, including migraine and chronic obstructive pulmonary disease[112]. - The company is actively expanding into chemical and biological drug fields, with several products in clinical phases I and II for various diseases[61]. - The R&D pipeline focuses on traditional Chinese medicine while expanding into metabolic, autoimmune, and neurological diseases, creating a diversified product matrix[146]. Market and Product Development - The company aims to enhance professional marketing and compliance through the "Doctor Pan Project," focusing on training and assessment for marketing personnel[16]. - The company has trained over 10,000 marketing personnel through the "Doctor Pan Project," enhancing their academic capabilities[34]. - The company is actively pursuing new strategies for market expansion and product development to enhance its competitive position in the pharmaceutical industry[111]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a budget of CNY 500 million allocated for this purpose[163]. - The company plans to launch three new products in the next fiscal year, focusing on traditional Chinese medicine and modern healthcare solutions[163]. - The company has established partnerships with three major hospitals to promote its products, aiming to increase brand visibility and credibility in the healthcare sector[163]. Corporate Governance - The company maintains a governance structure that ensures effective checks and balances among its decision-making bodies, enhancing shareholder value[149]. - The board of directors consists of 9 members with diverse expertise, including 3 independent directors, to support comprehensive decision-making[150]. - The company has established a long-term mechanism to prevent the controlling shareholder from misappropriating company funds, ensuring fair transactions[149]. - The company has not reported any significant differences in governance compared to regulatory requirements, ensuring operational independence from controlling shareholders[154]. - The company is in the process of electing new independent directors following the resignation of two current independent directors, ensuring compliance with governance standards[160]. Operational Efficiency - The company has established a comprehensive procurement center to optimize material procurement and control costs effectively[62]. - The production process adheres strictly to GMP standards, ensuring quality control throughout the manufacturing process[63]. - The company has implemented a comprehensive quality management system to control risks throughout the entire production process, ensuring consistent product quality[145]. - The company is committed to improving production quality management and enhancing supply chain management efficiency to meet market supply demands[141]. Strategic Initiatives - The company is committed to enhancing its innovation strategy, focusing on product innovation, academic innovation, and sales model innovation to achieve industrial scale effects[134]. - The company is accelerating the development of innovative drugs, targeting unmet clinical needs and focusing on high clinical value and market potential[139]. - AI technology will be integrated into the drug development process, optimizing research workflows and enhancing new drug development efficiency[140]. - The company is implementing a differentiated agency model to restore growth and expand the out-of-hospital market, focusing on core products and optimizing customer management[138]. Risk Management - The company faces risks from policy changes, particularly in drug procurement and medical insurance adjustments, which could significantly impact the pharmaceutical industry[143]. - The company has a dedicated team for risk management in R&D, ensuring systematic risk analysis and control throughout the drug development process[146]. - The company has established an Insider Information Management System to ensure compliance with relevant laws and regulations, with the chairman as the primary responsible person[153]. Employee Development - The company has established a talent development system to meet strategic growth needs, including programs for recent graduates and specialized training initiatives[189]. - The company conducts specialized training programs for key positions and skills, utilizing both internal and external resources to enhance employee capabilities[187]. - The company has established a performance-based compensation system that aligns employee incentives with company performance, ensuring a fair and competitive salary structure[186]. Acquisitions and Partnerships - The company completed the acquisition of 100% equity in Zhongxin Pharmaceutical, which has been included in the consolidated financial statements[26]. - The company completed the acquisition of 100% equity in Jiangsu Zhongxin Pharmaceutical Co., Ltd., which is now a wholly-owned subsidiary included in the financial statements[85]. - The company has been actively involved in expanding its market presence through acquisitions and strategic partnerships[174].

证券简称：康缘药业 证券代码：600557 公告编号：2025-009 江苏康缘药业股份有限公司 2024 年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2024 年度,公司通过集中竞价方式累计回购公司股份 12,338,346 股， 已支付金额为 185,909,622.90 元（含交易费用），并于 2025 年 2 月 6 日将本次 回购的股份全部注销，该金额视同现金分红，以此计算公司 2024 年度分红金额 占公司 2024 年度合并报表归属于母公司股东的净利润的比例已达 47.44%。 的股份全部注销。具体内容详见公司在上海证券交易所网站 www.sse.com.cn 披 露的公司《关于股份回购实施结果暨股份变动的公告》（公告编号：2025-001）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号 ——回购股份》的规定，上市公司以现金为对价，采用集中竞价方式、要约方 式回购股份的，当年已实施的股份回购金额视同现金分红金额，纳入该年度现 金分红的相关比 ...

4月2日，康缘药业（600557）发布2024年年报，公司营业收入为38.98亿元，同比下降19.86%；归母净 利润为3.92亿元，同比下降15.58%；扣非净利润为3.63亿元，同比下降27.29%。报告期内，公司核心产 品热毒宁注射液和银杏二萜内酯葡胺注射液业绩承压，导致整体营收和利润双双下滑。尽管公司在研发 和并购方面取得了一定进展，但面对行业政策压力和市场竞争，康缘药业的经营挑战依然严峻。 并购中新医药，生物药布局深化 2024年，康缘药业完成了对中新医药的100%股权收购，进一步丰富了公司的生物药管线。中新医药拥 有多个具有创新性和独有性的研发技术平台，尤其是在代谢性疾病和神经系统疾病领域，已有多个生物 创新药进入临床试验阶段。通过这次并购，康缘药业在生物药领域的布局得到了进一步深化，有助于公 司构建中药、化药和生物药协同发展的完整产业布局。 然而，并购带来的整合风险和成本压力也不容忽视。中新医药的研发项目尚处于早期阶段，未来能否成 功上市并取得市场认可仍存在不确定性。此外，并购后的整合工作也将对公司的管理能力和资源调配提 出更高要求。如何在短期内实现并购的协同效应，将是康缘药业未来面临的又一挑战 ...

前十大流通股东累计持有： 28825.35万股，累计占流通股比： 49.82%，较上期变化： -1068.57万股。 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 江苏康缘集团有限责任公司 | 17617.35 | 30.45 | 不变 | | 连云港康贝尔医疗器械有限公司 | 3187.06 | 5.51 | 不变 | | 中央汇金资产管理有限责任公司 | 1788.65 | 3.09 | 不变 | | 肖伟 | 1700.32 | 2.94 | 不变 | | 香港中央结算有限公司 | 1387.95 | 2.40 | -767.79 | | 上海银叶投资有限公司-银叶攻玉10号私募证券投资 | | | | | 基金 | 1194.52 | 2.06 | 不变 | | 大成基金-农业银行-大成中证金融资产管理计划 | 500.68 | 0.87 | -28.50 | | 南方基金-农业银行-南方中证金融资产管理计划 | 499.17 | 0.86 | -30.88 | | 博时基金-农业银行- ...

一、《药物临床试验批准通知书》主要内容 登录新浪财经APP 搜索【信披】查看更多考评等级 证券简称：康缘药业 证券代码：600557 公告编号：2025-006 江苏康缘药业股份有限公司 关于收到连参更年颗粒临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）近日收到国家药品监督管理局签发的连参更年颗粒《药 物临床试验批准通知书》。按照《上海证券交易所上市公司自律监管指引第3号一行业信息披露》的相 关要求，现将相关情况公告如下： ■ 连参更年颗粒审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2024年12月23日受 理的连参更年颗粒符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意本品开展用于 更年期综合征（阴虚火旺证）的临床试验。 二、药品研发及相关情况 连参更年颗粒处方源于临床经验方，功能主治为滋阴清热，宁心安神。用于更年期综合征（阴虚火旺 证），症见烘热出汗、五心烦热、失眠多梦、心悸怔忡、心烦不宁、眩晕耳鸣等。 临床前主要药效学 ...

证券简称：康缘药业 证券代码：600557 公告编号：2025-006 江苏康缘药业股份有限公司 连参更年颗粒处方源于临床经验方，功能主治为滋阴清热，宁心安神。用于更年 期综合征（阴虚火旺证），症见烘热出汗、五心烦热、失眠多梦、心悸怔忡、心烦不 宁、眩晕耳鸣等。 临床前主要药效学研究显示，连参更年颗粒在模型小鼠的影响试验中可减轻模型 动物子宫损伤并减少束缚应激后自发活动，可增加小鼠睡眠的入睡率，缩短入睡潜伏 期，延长睡眠时间，减少小鼠自发活动频次。毒理学研究显示，连参更年颗粒药物安 全性好，安全剂量范围较宽。我公司拥有该新药独立完整的知识产权。 关于收到连参更年颗粒临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）近日收到国家药品监督管理局 签发的连参更年颗粒《药物临床试验批准通知书》。按照《上海证券交易所上市公司 自律监管指引第 3 号—行业信息披露》的相关要求，现将相关情况公告如下： | 药品名称 | 连参更年颗粒 | | --- | --- | | 适应 ...

证券简称：康缘药业 证券代码：600557 公告编号：2025-004 江苏康缘药业股份有限公司 关于收到固本消疹颗粒临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局签发的固本消疹颗粒《药物临床试验批准通知书》。按照《上海证券交易所 上市公司自律监管指引第 3 号—行业信息披露》的相关要求，现将相关情况公告 如下： 固本消疹颗粒审批结论：根据《中华人民共和国药品管理法》及有关规定， 经审查，2024 年 12 月 10 日受理的固本消疹颗粒符合药品注册的有关要求，在 进一步完善临床试验方案的基础上，同意本品开展用于慢性自发性荨麻疹卫表不 固证的临床试验。 根据中华医学会皮肤性病学分会荨麻疹研究中心发布的《中国荨麻疹诊疗指 南（2022 版）》，荨麻疹是由于皮肤、黏膜小血管扩张及渗透性增加出现的一种 局限性水肿反应。临床表现为大小不等的风团伴瘙痒，约 20%的患者伴有血管性 水肿。慢性荨麻疹是指风团每天发作或间歇发作，持续时间＞6 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）控股子公司江苏康缘阳光 药业有限公司（以下简称"康缘阳光"）近日收到国家药品监督管理局签发的关 于淫羊藿总黄酮胶囊新增血管性痴呆适应症的《药物临床试验批准通知书》。按 照《上海证券交易所上市公司自律监管指引第 3 号—行业信息披露》的相关要 求，现将相关情况公告如下： | 药品名称 | 淫羊藿总黄酮胶囊 | | --- | --- | | 药品批件号 | 国药准字 Z20140012 | | 注册分类 | 中药改良型新药 2.3 类 | | 原功能主治 | 原发性骨质疏松症肾阳虚证 | | 增加适应症 | 血管性痴呆 | | 剂型 | 胶囊剂 | | 受理号 | CXZL2400088 | | 申请人 | 江苏康缘阳光药业有限公司 | 一、《药物临床试验批准通知书》主要内容 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2024 年 12 月 10 日受理的淫羊藿总黄酮胶囊临床试验申请符合药品注册的有关要求， 在进一步完 ...